Histone Deacetylase Inhibitor ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
127前頭側頭葉変性症5

127. 前頭側頭葉変性症


臨床試験数 : 90 薬物数 : 87 - (DrugBank : 30) / 標的遺伝子数 : 39 - 標的パスウェイ数 : 88
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-001489-85-BE
(EUCTR)
05/03/201524/10/2014A study to investigate 2 doses of investigational drug on patients with Prodromal to Moderate Frontotemporal Dementia with Granulin MutationA Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation
MedDRA version: 18.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: FRM-0334
INN or Proposed INN: Histone Deacetylase Inhibitor
Other descriptive name: EVP-0334
FORUM Pharmaceuticals Inc.NULLNot RecruitingFemale: yes
Male: yes
30Phase 2France;United States;Belgium;Netherlands;Italy;United Kingdom
2EUCTR2014-001489-85-GB
(EUCTR)
23/02/201512/08/2014A study to investigate 2 doses of investigational drug on patients with Prodromal to Moderate Frontotemporal Dementia with Granulin MutationA Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation
MedDRA version: 18.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: FRM-0334
INN or Proposed INN: Histone Deacetylase Inhibitor
Other descriptive name: EVP-0334
FORUM Pharmaceuticals Inc.NULLNot Recruiting Female: yes
Male: yes
30 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noFrance;United States;Belgium;Netherlands;Italy;United Kingdom
3EUCTR2014-001489-85-IT
(EUCTR)
22/12/201402/10/2014A study to investigate 2 doses of investigational drug on patients with Prodromal to Moderate Frontotemporal Dementia with Granulin MutationA Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation
MedDRA version: 17.0;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: FRM-0334
INN or Proposed INN: Histone Deacetylase Inhibitor
Other descriptive name: EVP-0334
FORUM Pharmaceuticals Inc.NULLNot RecruitingFemale: yes
Male: yes
30Phase 2France;United States;Belgium;Netherlands;United Kingdom;Italy
4EUCTR2014-001489-85-NL
(EUCTR)
19/12/201423/09/2014A study to investigate 2 doses of investigational drug on patients with Prodromal to Moderate Frontotemporal Dementia with Granulin MutationA Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation
MedDRA version: 18.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: FRM-0334
INN or Proposed INN: Histone Deacetylase Inhibitor
Other descriptive name: EVP-0334
FORUM Pharmaceuticals Inc.NULLNot RecruitingFemale: yes
Male: yes
30Phase 2France;United States;Belgium;Netherlands;Italy;United Kingdom
5NCT02149160
(ClinicalTrials.gov)
October 201420/5/2014Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin MutationA Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin MutationGranulin MutationDrug: FRM-0334;Drug: PlaceboFORUM Pharmaceuticals IncNULLActive, not recruiting21 Years75 YearsBoth30Phase 2United States;Belgium;France;Italy;Netherlands;United Kingdom